Pharmaceutical assets company PDL BioPharma Inc (NASDAQ:PDLI) reported on Monday the availability of the authorised generic of Tekturna, aliskiren hemifumarate in 150 mg and 300 mg tablets for the treatment of hypertension in adults and children six years of age and older in the US.

This market launch is being initiated by Prasco, LLC, d/b/a Prasco Laboratories, under an agreement with PDL's wholly owned subsidiary, Noden Pharma USA Inc.

In conjunction, Noden will continue to manufacture and commercialise prescription aliskiren products under the Tekturna and Tekturna HCT (aliskiren and hydrochlorothiazide) brands in the US and the Rasilez and Rasilez HCT brands in international markets (collectively, the Tekturna Products).

For the trailing 12 months ending 30 September 2018, the total Noden sales of the Tekturna Products in the US were USD45.1m, with 79% of sales for Tekturna.

A direct renin inhibitor, Tekturna has a unique mechanism of action in that it lowers blood pressure by blocking the enzyme renin. The authorised generic has the same drug formulation as Tekturna, concluded the company.